Genmab reports positive RA data for HuMax-CD20

Genmab released new Phase II data for HuMax-CD20 demonstrating its effectiveness as an experimental antibody therapy for rheumatoid arthritis. Although the drug--also called Ofatumumab--did not do better than MabThera, a competing drug from Roche, researchers said the data warranted a push into late-stage trials in the last half of this year. GlaxoSmithKline bought the global rights to HuMax-CD20 in a deal worth a potential $2.1 billion payoff. Initial research has focused on its utility as a treatment for blood cancers, but a big potential payoff would come with an approval for use against RA.

- see this release on the data
- check out the AFX report for more

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.